lycopeneWhat was measured
Measured, with no finding
646 endpoints
Show what was measuredHide what was measured
baseline serum β-carotene, cardiovascular death vs alive
decreases, p = 0.025
Females | 0.969 | 0.759 (0.025) | 0.864 (0.461) | 0.679 (0.033)
PMID 16837766 · one of two readings recorded this
baseline serum α-carotene, heart disease death vs alive
decreases, p = 0.034
α-carotene (μmol/L) | Males | 0.106 | 0.090 (0.076) | 0.081 (0.034) | 0.095 (0.391)
PMID 16837766 · one of two readings recorded this
baseline serum β-carotene, stroke death vs alive
decreases, p = 0.033
Females | 0.969 | 0.759 (0.025) | 0.864 (0.461) | 0.679 (0.033)
PMID 16837766 · one of two readings recorded this
baseline serum lycopene, cardiovascular death vs alive
no effect, p = 0.304
Females | 0.371 | 0.327 (0.304) | 0.248 (0.017) | 0.424 (0.539)
PMID 16837766 · one of two readings recorded this
baseline serum lycopene, cardiovascular death vs alive
no effect, p = 0.142
Lycopene (μmol/L) | Males | 0.258 | 0.221 (0.142) | 0.237 (0.607) | 0.194 (0.056)
PMID 16837766 · one of two readings recorded this
baseline serum lycopene, heart disease death vs alive
decreases, p = 0.017
Females | 0.371 | 0.327 (0.304) | 0.248 (0.017) | 0.424 (0.539)
PMID 16837766 · one of two readings recorded this
baseline serum lycopene, heart disease death vs alive
no effect, p = 0.607
Lycopene (μmol/L) | Males | 0.258 | 0.221 (0.142) | 0.237 (0.607) | 0.194 (0.056)
PMID 16837766 · one of two readings recorded this
baseline serum lycopene, stroke death vs alive
no effect, p = 0.539
Females | 0.371 | 0.327 (0.304) | 0.248 (0.017) | 0.424 (0.539)
PMID 16837766 · one of two readings recorded this
baseline serum lycopene, stroke death vs alive
no effect, p = 0.056
Lycopene (μmol/L) | Males | 0.258 | 0.221 (0.142) | 0.237 (0.607) | 0.194 (0.056)
PMID 16837766 · one of two readings recorded this
baseline serum total carotene, cardiovascular death vs alive
no effect, p = 0.057
Females | 1.587 | 1.321 (0.057) | 1.343 (0.214) | 1.296 (0.172)
PMID 16837766 · one of two readings recorded this
cardiovascular disease mortality by baseline serum lycopene (HPLC, log-transformed), Cox model 2 adjusted for sex, age, smoking, alcohol, BMI, systolic blood pressure, cholesterol, triglyceride and ALT
Not recorded as a finding: a direction is stated and the estimate does not support it
Using model 2, the hazard ratios for cardiovascular disease mortality also showed significantly low trends for serum values of α-carotene, β-carotene, and total carotene, and marginally significantly low trends for those of lycopene.
PMID 16837766 · one of two readings recorded this
cardiovascular disease mortality, Cox hazard ratio per log serum lycopene (HPLC), 3,061 Hokkaido residents, 11.9 years
model 2 (fully adjusted) gave only a marginally significant low trend for lycopene; lycopene is named only inside a list of carotenoids and the two models disagree on significance
Not recorded as a finding: another reason, stated per paper
Using model 2, the hazard ratios for cardiovascular disease mortality also showed significantly low trends for serum values of α-carotene, β-carotene, and total carotene, and marginally significantly low trends for those of lycopene.
PMID 16837766 · one of two readings recorded this
cardiovascular disease mortality
decreases
Cardiovascular disease | α-carotene | 3,059 | 80 | 0.52 (0.37- 0.74) | 0.000 | 0.55 (0.38- 0.79) | 0.001
PMID 16837766 · one of two readings recorded this
cardiovascular disease mortality
decreases, p = 0.001
Cardiovascular disease | α-carotene | 3,059 | 80 | 0.52 (0.37- 0.74) | 0.000 | 0.55 (0.38- 0.79) | 0.001
PMID 16837766 · one of two readings recorded this
cardiovascular disease mortality
decreases, p = 0.032
Lycopene | 3,059 | 80 | 0.73 (0.55-0.97) | 0.032 | 0.77 (0.57-1.04) | 0.088
PMID 16837766 · one of two readings recorded this
cardiovascular disease mortality
no effect, p = 0.088
Lycopene | 3,059 | 80 | 0.73 (0.55-0.97) | 0.032 | 0.77 (0.57-1.04) | 0.088
PMID 16837766 · one of two readings recorded this
cardiovascular disease mortality
decreases, p = 0.001
Total carotene | 3,059 | 80 | 0.54 (0.38-0.77) | 0.001 | 0.57 (0.40-0.83) | 0.003
PMID 16837766 · one of two readings recorded this
cardiovascular disease mortality
decreases, p = 0.003
Total carotene | 3,059 | 80 | 0.54 (0.38-0.77) | 0.001 | 0.57 (0.40-0.83) | 0.003
PMID 16837766 · one of two readings recorded this
heart disease mortality
decreases, p = 0.002
Heart disease | α-carotene | 3,059 | 40 | 0.45 (0.27-0.73) | 0.002 | 0.51 (0.30-0.86) | 0.012
PMID 16837766 · one of two readings recorded this
heart disease mortality
decreases, p = 0.012
Heart disease | α-carotene | 3,059 | 40 | 0.45 (0.27-0.73) | 0.002 | 0.51 (0.30-0.86) | 0.012
PMID 16837766 · one of two readings recorded this
heart disease mortality
no effect, p = 0.069
Lycopene | 3,059 | 40 | 0.68 (0.45-1.03) | 0.069 | 0.74 (0.48-1.13) | 0.163
PMID 16837766 · one of two readings recorded this
heart disease mortality
no effect, p = 0.163
Lycopene | 3,059 | 40 | 0.68 (0.45-1.03) | 0.069 | 0.74 (0.48-1.13) | 0.163
PMID 16837766 · one of two readings recorded this
heart disease mortality
decreases, p = 0.049
Total carotene | 3,059 | 40 | 0.60 (0.37-0.99) | 0.049 | 0.72 (0.41-1.23) | 0.228
PMID 16837766 · one of two readings recorded this
heart disease mortality
no effect, p = 0.228
Total carotene | 3,059 | 40 | 0.60 (0.37-0.99) | 0.049 | 0.72 (0.41-1.23) | 0.228
PMID 16837766 · one of two readings recorded this
stroke mortality
decreases, p = 0.027
Stroke | α-carotene | 3,059 | 37 | 0.56 (0.34-0.94) | 0.027 | 0.52 (0.31-0.88) | 0.016
PMID 16837766 · one of two readings recorded this
stroke mortality
decreases, p = 0.016
Stroke | α-carotene | 3,059 | 37 | 0.56 (0.34-0.94) | 0.027 | 0.52 (0.31-0.88) | 0.016
PMID 16837766 · one of two readings recorded this
stroke mortality
no effect, p = 0.21
Lycopene | 3,059 | 37 | 0.76 (0.50-1.17) | 0.210 | 0.78 (0.51-1.19) | 0.253
PMID 16837766 · one of two readings recorded this
stroke mortality
no effect, p = 0.253
Lycopene | 3,059 | 37 | 0.76 (0.50-1.17) | 0.210 | 0.78 (0.51-1.19) | 0.253
PMID 16837766 · one of two readings recorded this
stroke mortality
decreases, p = 0.005
Total carotene | 3,059 | 37 | 0.48 (0.29-0.80) | 0.005 | 0.45 (0.28-0.76) | 0.003
PMID 16837766 · one of two readings recorded this
stroke mortality
decreases, p = 0.003
Total carotene | 3,059 | 37 | 0.48 (0.29-0.80) | 0.005 | 0.45 (0.28-0.76) | 0.003
PMID 16837766 · one of two readings recorded this
diagnosed uterine leiomyoma
no effect
Total lycopene intake was not associated with diagnosed UL risk
PMID 17981250 · one of two readings recorded this
diagnosed uterine leiomyoma
increases, p = 0.003
for highest vs lowest quintile, relative risk = 1.36, 95% confidence interval 1.05 to 1.76; P(trend) = .003
PMID 17981250 · one of two readings recorded this
DNA damage by comet assay
decreases, p = 0.007
ANOVA revealed a significant decrease in DNA damage by the comet assay (p = 0.007)
PMID 18689558 · one of two readings recorded this
glucose, lipid profile and other biomarkers of lipid peroxidation
no effect
No significant inter- or intra-group differences were noted for glucose, lipid profile, or other biomarkers of lipid peroxidation at any dose/time point
PMID 18689558 · one of two readings recorded this
lymphocyte DNA damage by comet assay and urinary 8-hydroxydeoxyguanosine (8-OHdG) after 8 weeks of purified lycopene at 0, 6.5, 15 or 30 mg/day
decreases, p = 0.007
Not recorded as a finding: this platform holds no node for the endpoint
ANOVA revealed a significant decrease in DNA damage by the comet assay (p = 0.007), and a significant decrease in urinary 8-hydroxy deoxoguanosine (8-OHdG) at 8 weeks versus baseline (p = 0.0002), with 30 mg lycopene/day.
PMID 18689558 · one of two readings recorded this
plasma lycopene
increases, p = 0.05
Independent of the dose, plasma lycopene levels significantly increased in all lycopene supplemented groups versus placebo (p < 0.05)
PMID 18689558 · one of two readings recorded this
urinary 8-hydroxy deoxoguanosine (8-OHdG)
decreases, p = 0.0002
a significant decrease in urinary 8-hydroxy deoxoguanosine (8-OHdG) at 8 weeks versus baseline (p = 0.0002), with 30 mg lycopene/day
PMID 18689558 · one of two readings recorded this
urinary 8-hydroxy deoxyguanosine (8-OHdG) and lymphocyte DNA damage by comet assay after 8 weeks of purified lycopene at 0, 6.5, 15 or 30 mg/day
decreases, significant decrease in urinary 8-hydroxy deoxoguanosine (8-OHdG) at 8 weeks versus baseline, with 30 mg lycopene/day, p = 0.0002
Not recorded as a finding: this platform holds no node for the endpoint
ANOVA revealed a significant decrease in DNA damage by the comet assay (p = 0.007), and a significant decrease in urinary 8-hydroxy deoxoguanosine (8-OHdG) at 8 weeks versus baseline (p = 0.0002), with 30 mg lycopene/day.
PMID 18689558 · one of two readings recorded this
hip fracture
decreases, p = 0.01
Subjects with higher lycopene intake had lower risk of hip fracture (p =0.01)
PMID 19138129 · one of two readings recorded this
hip fracture
no effect, p = 0.1
A weak protective trend was observed for total beta-carotene for hip fracture alone, but associations did not reach statistical significance (p = 0.10)
PMID 19138129 · one of two readings recorded this
hip fracture
decreases, p = 0.02
Subjects in the highest tertile of total carotenoid intake had lower risk of hip fracture (p = 0.02)
PMID 19138129 · one of two readings recorded this
nonvertebral osteoporotic fracture
decreases, p = 0.02
Subjects with higher lycopene intake had lower risk of hip fracture (p =0.01) and nonvertebral fracture (p = 0.02)
PMID 19138129 · one of two readings recorded this
acceptability of treatment form (chocolate vs capsule)
modulates, p = 0.0001
a marked difference in acceptability between the two treatment forms (chocolate or capsule) was revealed (p < 0.0001)
PMID 19583878 · one of two readings recorded this
blood pressure change over time
no effect
Blood pressure changes over time within groups and between groups were not significant and independent of treatment
PMID 19583878 · one of two readings recorded this
blood pressure (median, 4-weekly) in prehypertensive adults given a tomato extract capsule with 15 mg lycopene per day vs placebo
no effect, Blood pressure changes over time within groups and between groups were not significant
Not recorded as a finding: the supporting sentence never names the compound
Blood pressure changes over time within groups and between groups were not significant and independent of treatment.
PMID 19583878 · one of two readings recorded this
median blood pressure (SBP/DBP not separately named) over 12 weeks, tomato extract capsule with 15 mg lycopene vs placebo capsule
no effect
Not recorded as a finding: the supporting sentence never names the compound
Blood pressure changes over time within groups and between groups were not significant and independent of treatment.
PMID 19583878 · one of two readings recorded this
weight and other characteristics
no effect
Weight and other characteristics did not change significantly during the trial
PMID 19583878 · one of two readings recorded this
prostate cancer risk, Gleason 2 to 6, per 10 μg/dL increase in serum lycopene
no effect
The odds ratios for a linear increase in lycopene (per 10 μg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively
PMID 21335507 · one of two readings recorded this
prostate cancer risk, Gleason 7 to 10, per 10 μg/dL increase in serum lycopene
no effect
The odds ratios for a linear increase in lycopene (per 10 μg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively
PMID 21335507 · one of two readings recorded this
prostate cancer risk, Gleason 8 to 10, per 10 μg/dL increase in serum lycopene
no effect
The odds ratios for a linear increase in lycopene (per 10 μg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively
PMID 21335507 · one of two readings recorded this
risk of cancer diagnosed following elevated PSA or abnormal DRE, per 10 μg/dL increase in lycopene
decreases
In the placebo arm, a 10 μg/dL increase in lycopene was associated with a 7% (95% CI: 14-0) reduced risk of cancer diagnosed following an elevated PSA or abnormal DRE
PMID 21335507 · one of two readings recorded this
risk of cancer diagnosed without a biopsy prompt, per 10 μg/dL increase in lycopene
increases
a 10 μg/dL increase in lycopene was also associated with an 8% (95% CI: 1-16) increased risk of cancer diagnosed without a biopsy prompt
PMID 21335507 · one of two readings recorded this
plasma lycopene concentration
increases, mean 0.74 to 1.43 umol/L in the lycopene group
Not recorded as a finding: no outcome node for plasma lycopene concentration
For the men receiving lycopene, the mean lycopene concentration increased from 0.74 ± 0.39 to 1.43 ± 0.61 μmol/L in plasma (P < 0.0001) and from 0.45 ± 0.53 to 0.59 ± 0.47 pmol/mg in prostate tissue (P = 0.005).
PMID 21430075 · one of two readings recorded this
plasma lycopene concentration
increases, p = 0.0001
For the men receiving lycopene, the mean lycopene concentration increased from 0.74 ± 0.39 to 1.43 ± 0.61 μmol/L in plasma (P < 0.0001)
PMID 21430075 · one of two readings recorded this
plasma malondialdehyde (lipid peroxidation product) after 30 mg/d lycopene as tomato oleoresin vs placebo for 21 days
no effect, No significant changes in the lipid peroxidation product malondialdehyde in plasma
Not recorded as a finding: the paper never states the instrument the node requires
No significant changes in the DNA oxidation product 8-oxo-deoxyguanosine and the lipid peroxidation product malondialdehyde were observed in prostate tissue and plasma, respectively, as a result of lycopene administration.
PMID 21430075 · one of two readings recorded this
prostate tissue 8-oxo-deoxyguanosine (DNA oxidation) and plasma malondialdehyde (lipid peroxidation)
no effect
No significant changes in the DNA oxidation product 8-oxo-deoxyguanosine and the lipid peroxidation product malondialdehyde were observed in prostate tissue and plasma, respectively, as a result of lycopene administration
PMID 21430075 · one of two readings recorded this
prostate tissue lycopene concentration
increases, p = 0.005
and from 0.45 ± 0.53 to 0.59 ± 0.47 pmol/mg in prostate tissue (P = 0.005)
PMID 21430075 · one of two readings recorded this
androgen and estrogen metabolism pathway modulation, higher vs lower fish consumers
modulates, p = 0.029
modulation of androgen and estrogen metabolism in men who routinely consumed more fish (p = 0.029) and tomato (p = 0.008) compared to men who ate less
PMID 21912659 · one of two readings recorded this
androgen and estrogen metabolism pathway modulation, higher vs lower tomato consumers
modulates, p = 0.008
modulation of androgen and estrogen metabolism in men who routinely consumed more fish (p = 0.029) and tomato (p = 0.008) compared to men who ate less
PMID 21912659 · one of two readings recorded this
arachidonic acid metabolism pathway modulation (prostate gene expression)
modulates, p = 0.01
modulation of arachidonic acid metabolism (p = 0.01) was observed after 3 months of fish oil supplementation compared with the placebo group
PMID 21912659 · one of two readings recorded this
gene expression in morphologically normal prostate tissue by cDNA microarray, differential gene expression and pathway analysis after 3 months of lycopene vs placebo
no effect, no significant individual genes associated with supplementation of lycopene
Not recorded as a finding: this platform holds no node for the endpoint
We did not detect significant individual genes associated with dietary intake and supplementation of lycopene and fish oil.
PMID 21912659 · one of two readings recorded this
gene expression in morphologically normal prostate tissue, cDNA microarray, individual genes and pathway analysis after 3 months of lycopene vs placebo
no effect
Not recorded as a finding: this platform holds no node for the endpoint
We did not detect significant individual genes associated with dietary intake and supplementation of lycopene and fish oil.
PMID 21912659 · one of two readings recorded this
individual differentially expressed genes
no effect
Global gene expression analysis revealed no significant individual genes that were associated with high intake of fish or tomato at baseline or after 3 months of supplementation with lycopene or fish oil
PMID 21912659 · one of two readings recorded this
Nrf2-mediated oxidative stress response pathway modulation (prostate gene expression)
modulates, p = 0.01
modulation of nuclear factor (erythroid derived-2) factor 2 or Nrf2-mediated oxidative stress response for either supplement versus placebo (fish oil: p = 0.01, lycopene: p = 0.001)
PMID 21912659 · one of two readings recorded this
Nrf2-mediated oxidative stress response pathway modulation (prostate gene expression)
modulates, p = 0.001
modulation of nuclear factor (erythroid derived-2) factor 2 or Nrf2-mediated oxidative stress response for either supplement versus placebo (fish oil: p = 0.01, lycopene: p = 0.001)
PMID 21912659 · one of two readings recorded this
circulating lycopene level, pooled mean difference
no effect, MD 0.39 ug/mL (95% CI -0.19, 0.98)
Not recorded as a finding: Manipulation check on the compound's own level; no outcome node for circulating lycopene
The level of lycopene was also not statistically different in men randomised to receive lycopene and the comparison group (MD 0.39 µg/mL (micrograms/millilitre), 95% CI -0.19, 0.98).
PMID 22071840 · one of two readings recorded this
incidence of prostate cancer (single study)
unclear
Only one study reported incidence of prostate cancer (10% in the lycopene group versus 30% in control group)
PMID 22071840 · one of two readings recorded this
lycopene level
no effect
The level of lycopene was also not statistically different in men randomised to receive lycopene and the comparison group (MD 0.39 µg/mL (micrograms/millilitre), 95% CI -0.19, 0.98)
PMID 22071840 · one of two readings recorded this
prostate cancer incidence, single study only
10% in the lycopene group versus 30% in control
Not recorded as a finding: No pooled estimate; one trial's raw proportions with no test statistic
Only one study reported incidence of prostate cancer (10% in the lycopene group versus 30% in control group).
PMID 22071840 · one of two readings recorded this
prostate cancer incidence, single trial, percentage of men with prostate cancer
10% in the lycopene group versus 30% in control group
Not recorded as a finding: Only one study reported it, so nothing is pooled and the sentence gives no direction word or test
Only one study reported incidence of prostate cancer (10% in the lycopene group versus 30% in control group).
PMID 22071840 · one of two readings recorded this
PSA level
no effect
Meta-analysis indicated no statistical difference in PSA levels between men randomised to receive lycopene and the comparison group (MD (mean difference) -0.34, 95% CI (confidence interval) -2.01, 1.32)
PMID 22071840 · one of two readings recorded this
cardiac event-free survival (cardiac death or hospitalisation) at 1 year, Cox proportional hazards, by median split of dietary lycopene from 4-day food diaries
increases, higher lycopene intake associated with longer cardiac event-free survival, p = 0.003
Not recorded as a finding: this platform holds no node for the endpoint
Higher lycopene intake was associated with longer cardiac event-free survival compared with lower lycopene intake (p = 0.003).
PMID 23076979 · one of two readings recorded this
cardiac event-free survival (death or hospitalisation) over 1 year, Cox proportional hazards, by median split of dietary lycopene from 4-day food diaries in heart failure patients
increases, higher lycopene intake associated with longer cardiac event-free survival, p = 0.003, n = 212
Not recorded as a finding: this platform holds no node for the endpoint
Higher lycopene intake was associated with longer cardiac event-free survival compared with lower lycopene intake (p = 0.003).
PMID 23076979 · one of two readings recorded this
cardiac event-free survival, low vs high lycopene
decreases, p = 0.027
> 3 g/day HR = 3.01; p = 0.027
PMID 23076979 · one of two readings recorded this
cardiac event-free survival
increases, p = 0.003, n = 212
Higher lycopene intake was associated with longer cardiac event-free survival compared with lower lycopene intake (p = 0.003)
PMID 23076979 · one of two readings recorded this
DNA tail length by comet assay (lymphocyte DNA damage), pooled mean difference; LDL oxidation lag time also pooled
decreases, MD -6.27 (95% CI -10.74, -1.90), p = 0.006
Not recorded as a finding: this platform holds no node for the endpoint
Our results indicate that lycopene supplementation significantly decreases the DNA tail length, as determined using comet assays, with a mean difference (MD) of -6.27 [95% confidence interval (CI) -10.74, -1.90] (P=.006) between the lycopene intervention groups and the control groups.
PMID 23631493 · one of two readings recorded this
DNA tail length (comet assay)
decreases, p = 0.006
with a mean difference (MD) of -6.27 [95% confidence interval (CI) -10.74, -1.90] (P=.006) between the lycopene intervention groups and the control groups
PMID 23631493 · one of two readings recorded this
low-density lipoprotein lag time
no effect, p = 0.24
Lycopene supplementation does not significantly prolong the lag time of low-density lipoprotein (MD 3.76 [95% CI -2.48, 10.01]; P=.24)
PMID 23631493 · one of two readings recorded this
diastolic blood pressure change, individual trial
unclear
Paterson, 2006,, U.K, Europe | single-blind, RCT | L: carotenoid-rich canned soups C: carotenoid-poor canned soups | L: 4.5 C: 0 | 4 weeks | SBP: 1 vs. 2 DBP: 1 vs. 2 | healthy adult, 12 m/24 f, 43.5 ± 23.5 years | L: 36 C: 36 | included | by a three-day estimated diet diary
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.087
the overall pooled estimate of lycopene on DBP was −3.809 mmHg (95% CI, −8.177, 0.560, p = 0.087)
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.097, n = 5
All | 5 | −0.315 (−0.687, 0.057) | 0.097 | 0.555 | 0
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.108, n = 3
<80 mmHg | 3 | −0.308 (−0.683, 0.068) | 0.108 | 0.927 | 0.0
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.086, n = 3
>8 weeks | 3 | −0.328 (−0.703, 0.046) | 0.086 | 0.434 | 0.0
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.862, n = 2
Asia | 2 | −0.408 (−5.003, 4.188) | 0.862 | 0.095 | 64.1
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.108, n = 3
Other regions | 3 | −0.308 (−0.683, 0.068) | 0.108 | 0.927 | 0.0
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.111, n = 2
<12 mg/day | 2 | −0.305 (−0.681, 0.071) | 0.111 | 0.750 | 0.0
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.159, n = 2
No-support by funding | 2 | −1.956 (−4.674, 0.763) | 0.159 | 0.572 | 0
PMID 24051501 · one of two readings recorded this
diastolic blood pressure, pooled net change
no effect, p = 0.139, n = 3
Support by funding | 3 | −0.284 (−0.659, 0.092) | 0.139 | 0.530 | 0
PMID 24051501 · one of two readings recorded this
publication bias, DBP (Egger test)
no effect, p = 0.751
results of Funnel plots and Egger’s test of trials showed no publication bias (p = 0.192 and 0.751 for SBP and DBP, respectively)
PMID 24051501 · one of two readings recorded this
publication bias, SBP (Egger test)
no effect, p = 0.192
results of Funnel plots and Egger’s test of trials showed no publication bias (p = 0.192 and 0.751 for SBP and DBP, respectively)
PMID 24051501 · one of two readings recorded this
systolic blood pressure change, individual trial
unclear
Paterson, 2006,, U.K, Europe | single-blind, RCT | L: carotenoid-rich canned soups C: carotenoid-poor canned soups | L: 4.5 C: 0 | 4 weeks | SBP: 1 vs. 2 DBP: 1 vs. 2 | healthy adult, 12 m/24 f, 43.5 ± 23.5 years | L: 36 C: 36 | included | by a three-day estimated diet diary
PMID 24051501 · one of two readings recorded this
systolic blood pressure change, individual trial
unclear
Kim, 2011, Yonsei, Asia | double-blind, RCT | L: tomato extract capsule (Lyc-O-Mato) C: placebo capsule | L1: 6 L2: 15 C: 0 | 8 weeks | SBP: −3.2 vs. −0.6 | healthy male, smoker or alcohol-drinker, low intake of fruits and vegetables; male, 33.5–34.8 years | L1:41 L2: 37 C: 38 | negligible | by 24-h recall method and semi-quantitative food frequency questionnaire
PMID 24051501 · one of two readings recorded this
systolic blood pressure (mmHg), pooled weighted mean difference of net change, lycopene supplement versus placebo or lycopene-free diet; diastolic blood pressure also pooled, over 40 words of prose in its only sentence
pooled SBP WMD -4.953 mmHg (95% CI -8.820, -1.086), p = 0.012
Not recorded as a finding: the direction is carried only as a signed number
The overall pooled estimate of the lycopene treatment on SBP was −4.953 mmHg (95% CI, −8.820, −1.086, p = 0.012).
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
decreases, p = 0.012, n = 6
The overall pooled estimate of the lycopene treatment on SBP was −4.953 mmHg (95% CI, −8.820, −1.086, p = 0.012)
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
decreases, p = 0.012, n = 6
All | 6 | −4.953 (−8.820, −1.086) | 0.012 | 0.034 | 58.5
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
no effect, p = 0.467, n = 3
<120 mmHg | 3 | −1.441 (−5.320, 2.439) | 0.467 | 0.731 | 0.0
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
no effect, p = 0.056, n = 4
>8 weeks | 4 | −4.324 (−8.753, 0.105) | 0.056 | 0.100 | 52.1
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
decreases, p = 0.002, n = 3
Asia | 3 | −7.661 (−12.480, −2.842) | 0.002 | 0.069 | 62.7
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
no effect, p = 0.524, n = 3
Other regions | 3 | −1.368 (−5.573, 2.838) | 0.524 | 0.723 | 0.0
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
no effect, p = 0.397, n = 2
<12 mg/day | 2 | −1.953 (−6.473, 2.568) | 0.397 | 0.680 | 0.0
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
no effect, p = 0.174, n = 2
No-support by funding | 2 | −5.363 (−13.095, 2.369) | 0.174 | 0.041 | 76.1
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled net change
no effect, p = 0.1, n = 4
Support by funding | 4 | −4.481 (−9.821, 0.859) | 0.100 | 0.061 | 59.3
PMID 24051501 · one of two readings recorded this
systolic blood pressure, pooled weighted mean difference (mmHg) of lycopene supplement versus control across six trial data sets; acquisition protocol not stated
WMD -4.953 mmHg (95% CI, -8.820, -1.086, p = 0.012), p = 0.012
Not recorded as a finding: the direction is carried only as a signed number
The overall pooled estimate of the lycopene treatment on SBP was −4.953 mmHg (95% CI, −8.820, −1.086, p = 0.012).
PMID 24051501 · one of two readings recorded this
systolic blood pressure, sensitivity analysis (fixed-effect), highest estimate
decreases
while analysis using fixed-effect model showed that no trials had substantial influence on the pooled analysis, and the results ranged from −4.128 (95% CI: −7.024, −1.233) to −5.738 (95% CI: −9.945, −1.530) mmHg
PMID 24051501 · one of two readings recorded this
systolic blood pressure, sensitivity analysis (fixed-effect), lowest estimate
decreases
while analysis using fixed-effect model showed that no trials had substantial influence on the pooled analysis, and the results ranged from −4.128 (95% CI: −7.024, −1.233) to −5.738 (95% CI: −9.945, −1.530) mmHg
PMID 24051501 · one of two readings recorded this
correlation between serum and dietary lycopene
no effect
No correlation between serum and dietary lycopene was detected
PMID 24180552 · one of two readings recorded this
correlation of serum lycopene with prior nutritional supplement use
decreases
A significant positive correlation between serum lycopene, weight, and body mass index, and a negative correlation between serum lycopene and piror nutritional supplement use was detected
PMID 24180552 · one of two readings recorded this
correlation of serum lycopene with weight and body mass index
increases
A significant positive correlation between serum lycopene, weight, and body mass index, and a negative correlation between serum lycopene and piror nutritional supplement use was detected
PMID 24180552 · one of two readings recorded this
gastrointestinal tolerance of tomato juice
no effect
TJ was well tolerated without any gastrointestinal side effects
PMID 24180552 · one of two readings recorded this
serum lycopene change from baseline to endpoint
increases
increased serum lycopene levels were observed in the 8 and 12 oz groups from baseline to endpoint
PMID 24180552 · one of two readings recorded this
serum lycopene concentration by liquid chromatography-mass spectrometry after daily tomato juice (4, 8 or 12 oz)
increases, increased serum lycopene levels in the 8 and 12 oz groups from baseline to endpoint
Not recorded as a finding: this platform holds no node for the endpoint
TJ was well tolerated without any gastrointestinal side effects, and increased serum lycopene levels were observed in the 8 and 12 oz groups from baseline to endpoint.
PMID 24180552 · one of two readings recorded this
serum lycopene concentration, liquid chromatography-mass spectrometry, after daily tomato juice during radiotherapy
increases
Not recorded as a finding: this platform holds no node for the endpoint
TJ was well tolerated without any gastrointestinal side effects, and increased serum lycopene levels were observed in the 8 and 12 oz groups from baseline to endpoint.
PMID 24180552 · one of two readings recorded this
weight change
no effect
Despite no reported change in dietary intake, non-significant weight loss was observed in the control group but not the intervention group participants
PMID 24180552 · one of two readings recorded this
lethal prostate cancer, top versus bottom quintile of dietary lycopene, Cox HR
decreases, HR 0.72; 95% CI 0.56 to 0.94
Not recorded as a finding: no node for lethal prostate cancer; the incidence node covers total diagnoses only
Higher lycopene intake was inversely associated with total prostate cancer and more strongly with lethal prostate cancer (top vs bottom quintile: HR = 0.72; 95% CI = 0.56 to 0.94; P(trend) = .04).
PMID 24463248 · one of two readings recorded this
lethal prostate cancer, top vs bottom quintile of lycopene intake
decreases, p = 0.04
Not recorded as a finding: no outcome node for lethal prostate cancer
Higher lycopene intake was inversely associated with total prostate cancer and more strongly with lethal prostate cancer (top vs bottom quintile: HR = 0.72; 95% CI = 0.56 to 0.94; P(trend) = .04).
PMID 24463248 · one of two readings recorded this
lethal prostate cancer
decreases, p = 0.04
top vs bottom quintile: HR = 0.72; 95% CI = 0.56 to 0.94; P(trend) = .04
PMID 24463248 · one of two readings recorded this
lethal prostate cancer
decreases, p = 0.009
for lethal prostate cancer: HR = 0.47; 95% CI = 0.29 to 0.75; P trend = .009
PMID 24463248 · one of two readings recorded this
C-reactive protein change
no effect
C-reactive protein levels decreased significantly in the intervention group in women and but not in men (P = .04)
PMID 24651682 · one of two readings recorded this
C-reactive protein change
decreases, p = 0.04
C-reactive protein levels decreased significantly in the intervention group in women and but not in men (P = .04)
PMID 24651682 · one of two readings recorded this
C-reactive protein, postintervention
The postintervention CRP level for women was 4.5 ± 3.6 mg/dL and for men was 2.4 ± 2.1 mg/dL
PMID 24651682 · one of two readings recorded this
C-reactive protein, postintervention
The postintervention CRP level for women was 4.5 ± 3.6 mg/dL and for men was 2.4 ± 2.1 mg/dL
PMID 24651682 · one of two readings recorded this
C-reactive protein, preintervention
The preintervention CRP level for women was 5.9 ± 3.7 mg/dL and for men was 2.2 ± 2.1 mg/dL
PMID 24651682 · one of two readings recorded this
C-reactive protein, preintervention
The preintervention CRP level for women was 5.9 ± 3.7 mg/dL and for men was 2.2 ± 2.1 mg/dL
PMID 24651682 · one of two readings recorded this
plasma lycopene
increases, p = 0.002
Plasma lycopene levels increased in the intervention group compared with the usual care group (0.51 μmol/L to 0.76 μmol/L, P = .002; 0.56 μmol/L to 0.58 μmol/L)
PMID 24651682 · one of two readings recorded this
plasma lycopene
no effect
Plasma lycopene levels increased in the intervention group compared with the usual care group (0.51 μmol/L to 0.76 μmol/L, P = .002; 0.56 μmol/L to 0.58 μmol/L)
PMID 24651682 · one of two readings recorded this
serum C-reactive protein (CRP) in heart failure patients after 30 days of V8 vegetable juice providing 29.4 mg lycopene/day vs usual care
decreases, CRP decreased in women but not in men, p = 0.04
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
C-reactive protein levels decreased significantly in the intervention group in women and but not in men (P = .04).
PMID 24651682 · one of two readings recorded this
serum C-reactive protein in heart failure patients after 30 days of V8 vegetable juice (29.4 mg lycopene/day) versus usual care
decreases, decrease in women only, not in men, p = 0.04
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
C-reactive protein levels decreased significantly in the intervention group in women and but not in men (P = .04).
PMID 24651682 · one of two readings recorded this
mucinous ovarian cancer risk
no effect, n = 3
Histologically, the OR for serous ovarian cancer and mucinous ovarian cancer was 0.744 (95% CI, 0.545–1.016; n = 4) and 0.878 (95% CI, 0.554–1.393; n = 3), respectively
PMID 24810584 · one of two readings recorded this
ovarian cancer risk by dietary lycopene intake (food-frequency questionnaire), highest versus lowest category, pooled OR, postmenopausal-dominant women
OR 0.963 (95% CI 0.859-1.080), not significant
Not recorded as a finding: this platform holds no node for the endpoint
Dietary lycopene consumption decreased the risk of ovarian cancer by 3.7% (OR, 0.963; 95% CI, 0.859–1.080), and no heterogeneity was observed across the studies (p = 0.336, I2 = 11.6%).
PMID 24810584 · one of two readings recorded this
ovarian cancer risk in postmenopausal women, pooled OR for highest versus lowest dietary lycopene intake
OR 0.963 (95% CI 0.859-1.080), I2 = 11.6%; interval includes the null
Not recorded as a finding: this platform holds no node for the endpoint
Dietary lycopene consumption decreased the risk of ovarian cancer by 3.7% (OR, 0.963; 95% CI, 0.859–1.080), and no heterogeneity was observed across the studies (p = 0.336, I2 = 11.6%).
PMID 24810584 · one of two readings recorded this
ovarian cancer risk, sensitivity analysis highest pooled OR
no effect
No study had a substantial effect on the final risk estimate; the pooled OR varied from 0.938 to 0.981
PMID 24810584 · one of two readings recorded this
ovarian cancer risk, sensitivity analysis lowest pooled OR
no effect
No study had a substantial effect on the final risk estimate; the pooled OR varied from 0.938 to 0.981
PMID 24810584 · one of two readings recorded this
ovarian cancer risk
no effect, p = 0.336, n = 10
Dietary lycopene consumption decreased the risk of ovarian cancer by 3.7% (OR, 0.963; 95% CI, 0.859–1.080), and no heterogeneity was observed across the studies (p = 0.336, I2 = 11.6%)
PMID 24810584 · one of two readings recorded this
ovarian cancer risk
no effect, n = 7
The pooled OR for case-control studies and prospective studies was 0.981 (95% CI, 0.846–1.139; n = 7) and 0.871 (95% CI, 0.616–1.233; n = 3), respectively
PMID 24810584 · one of two readings recorded this
ovarian cancer risk
no effect, n = 3
omitting the studies with a recall duration of <1 year resulted in an OR of 0.973 (95% CI, 0.823–1.149; n = 3)
PMID 24810584 · one of two readings recorded this
ovarian cancer risk
no effect, n = 3
The pooled OR for case-control studies and prospective studies was 0.981 (95% CI, 0.846–1.139; n = 7) and 0.871 (95% CI, 0.616–1.233; n = 3), respectively
PMID 24810584 · one of two readings recorded this
ovarian cancer risk
no effect, n = 7
The final risk estimate for studies conducted in and outside of the US was 0.923 (95% CI, 0.770–1.106; n = 7) and 1.026 (95% CI, 0.849–1.240; n = 3), respectively
PMID 24810584 · one of two readings recorded this
ovarian cancer risk
no effect, n = 3
The final risk estimate for studies conducted in and outside of the US was 0.923 (95% CI, 0.770–1.106; n = 7) and 1.026 (95% CI, 0.849–1.240; n = 3), respectively
PMID 24810584 · one of two readings recorded this
ovarian cancer risk
no effect, n = 7
Limiting the analysis to studies with higher response rates (>90%) resulted in an OR of 0.967 (95% CI, 0.849–1.102; n = 7)
PMID 24810584 · one of two readings recorded this
publication bias (Begg test)
no effect, p = 0.251
Funnel plots (as displayed in Figure 2) with Begg's and Egger's tests did not support the existence of publication bias (Begg, p = 0.251; Egger, p = 0.406)
PMID 24810584 · one of two readings recorded this
publication bias (Egger test)
no effect, p = 0.406
Funnel plots (as displayed in Figure 2) with Begg's and Egger's tests did not support the existence of publication bias (Begg, p = 0.251; Egger, p = 0.406)
PMID 24810584 · one of two readings recorded this
serous ovarian cancer risk
no effect, n = 4
Histologically, the OR for serous ovarian cancer and mucinous ovarian cancer was 0.744 (95% CI, 0.545–1.016; n = 4) and 0.878 (95% CI, 0.554–1.393; n = 3), respectively
PMID 24810584 · one of two readings recorded this
publication bias (Begg test)
no effect, p = 0.293
Testing publication bias using funnel plots and Egger's test did not produce statistically significant results (Begg, p = 0.293; Egger, p = 0.277)
PMID 24848940 · one of two readings recorded this
publication bias (Egger test)
no effect, p = 0.277
Testing publication bias using funnel plots and Egger's test did not produce statistically significant results (Begg, p = 0.293; Egger, p = 0.277)
PMID 24848940 · one of two readings recorded this
stroke risk (occurrence or mortality)
decreases, p = 0.234, n = 7
Specifically, lycopene decreased stroke risk by 19.3% (RR = 0.807, 95% CI = 0.680–0.957), and no heterogeneity was observed (p = 0.234, I2 = 25.5%)
PMID 24848940 · one of two readings recorded this
stroke risk, sensitivity analysis omitting Hirvonen et al
no effect
In the sensitivity analyses, omitting the trial of Hirvonen et al resulted in an insignificant reduction in stroke risk (RR = 0.860, 95% CI = 0.704–1.051)
PMID 24848940 · one of two readings recorded this
stroke risk, sensitivity range of pooled estimates (highest)
decreases
The resulting estimates varied from 0.754 (95% CI = 0.644–0.884) to 0.820 (95% CI = 0.701–0.958)
PMID 24848940 · one of two readings recorded this
stroke risk, sensitivity range of pooled estimates (lowest)
decreases
The resulting estimates varied from 0.754 (95% CI = 0.644–0.884) to 0.820 (95% CI = 0.701–0.958)
PMID 24848940 · one of two readings recorded this
stroke risk
decreases, n = 3
Circulating lycopene effectively decreased stroke risk (RR = 0.693, 95% CI = 0.503–0.954, n = 3), but dietary lycopene did not show the same effect (RR = 0.862, 95% CI, 0.688–1.080, n = 4)
PMID 24848940 · one of two readings recorded this
stroke risk
no effect, n = 4
Circulating lycopene effectively decreased stroke risk (RR = 0.693, 95% CI = 0.503–0.954, n = 3), but dietary lycopene did not show the same effect (RR = 0.862, 95% CI, 0.688–1.080, n = 4)
PMID 24848940 · one of two readings recorded this
stroke risk
decreases
Stratifying the results by number of cases showed that excluding studies with fewer than 100 cases resulted in a significant difference (RR = 0.771, 95% CI = 0.654–0.909)
PMID 24848940 · one of two readings recorded this
stroke risk
no effect
Lycopene significantly decreased the risk of stroke among male subjects (RR = 0.738, 95% CI = 0.585–0.931; n = 4) but not significantly among females (RR = 0.910, 95% CI = 0.571–1.451) or combined subjects (RR = 0.931, 95% CI = 0.684–1.266)
PMID 24848940 · one of two readings recorded this
stroke risk
no effect
Lycopene significantly decreased the risk of stroke among male subjects (RR = 0.738, 95% CI = 0.585–0.931; n = 4) but not significantly among females (RR = 0.910, 95% CI = 0.571–1.451) or combined subjects (RR = 0.931, 95% CI = 0.684–1.266)
PMID 24848940 · one of two readings recorded this
stroke risk
decreases, n = 4
Lycopene significantly decreased the risk of stroke among male subjects (RR = 0.738, 95% CI = 0.585–0.931; n = 4) but not significantly among females (RR = 0.910, 95% CI = 0.571–1.451) or combined subjects (RR = 0.931, 95% CI = 0.684–1.266)
PMID 24848940 · one of two readings recorded this
stroke risk
decreases, n = 2
The pooled RR for stroke was 0.655 (95% CI = 0.491–0.874; n = 2) for studies conducted in Europe, and 0.917 (95% CI, 0.760–1.107; n = 5) outside of Europe
PMID 24848940 · one of two readings recorded this
stroke risk
no effect, n = 5
The pooled RR for stroke was 0.655 (95% CI = 0.491–0.874; n = 2) for studies conducted in Europe, and 0.917 (95% CI, 0.760–1.107; n = 5) outside of Europe
PMID 24848940 · one of two readings recorded this
baseline EDV, CVD patients vs healthy volunteers
decreases, p = 0.008
At baseline, CVD patients had impaired EDV compared with HV (30% lower; 95% CI: -45% to -10%, P = 0.008)
PMID 24911964 · one of two readings recorded this
baseline LDL cholesterol, CVD patients vs healthy volunteers
decreases, p = 0.001
despite lower LDL cholesterol (1.2 mmol/L lower, 95% CI: -1.6 to -0.9 mmol/L, P<0.001)
PMID 24911964 · one of two readings recorded this
blood pressure, arterial stiffness, lipids and hsCRP
no effect
Blood pressure, arterial stiffness, lipids and hsCRP levels were unchanged for lycopene vs. placebo treatment groups in the CVD arm as well as the HV arm
PMID 24911964 · one of two readings recorded this
blood pressure, setting not stated
no effect
Not recorded as a finding: grouped with arterial stiffness and lipids in one sentence; blood pressure type and acquisition not stated, so no single node fits
Blood pressure, arterial stiffness, lipids and hsCRP levels were unchanged for lycopene vs. placebo treatment groups in the CVD arm as well as the HV arm.
PMID 24911964 · one of two readings recorded this
endothelium-dependent vasodilatation (EDV) forearm response to acetylcholine
increases, p = 0.03
EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo) without changes to EIDV, or basal NO responses
PMID 24911964 · one of two readings recorded this
endothelium-dependent vasodilatation (EDV)
no effect
HVs did not show changes in EDV after lycopene treatment
PMID 24911964 · one of two readings recorded this
endothelium-independent vasodilatation (EIDV) and basal NO responses
no effect
EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo) without changes to EIDV, or basal NO responses
PMID 24911964 · one of two readings recorded this
forearm endothelium-dependent vasodilatation to intra-arterial acetylcholine, venous plethysmography
increases, EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo), p = 0.03
Not recorded as a finding: no_outcome_node: forearm blood-flow response is not flow-mediated dilation; no node for it
EDV in CVD patients post-lycopene improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo) without changes to EIDV, or basal NO responses.
PMID 24911964 · both readings recorded this
post-therapy EDV in lycopene-treated CVD patients vs healthy volunteers at baseline
no effect, p = 0.85
Post-therapy EDV responses for lycopene-treated CVD patients were similar to HVs at baseline (2% lower, 95% CI: -30% to +30%, P = 0.85)
PMID 24911964 · one of two readings recorded this
baseline-corrected 12 h AUC of total lycopene in the plasma triglyceride-rich lipoprotein fraction, HPLC-DAD-MS/MS, after 10 mg lycopene from tangerine versus red tomato juice
increases, approximately 8.5 times more bioavailable from tangerine than red tomato juice
Not recorded as a finding: the comparison was against another active treatment
Lycopene from tangerine tomato juice was, on average, approximately 8.5 times more bioavailable compared to red tomato juice.
PMID 25620547 · one of two readings recorded this
lycopene AUC in TRL, males vs females (tangerine juice)
increases, p = 0.004, n = 11
all males had higher AUC values for lycopene on tangerine tomatoes than all females, a statistically significant increase (P = 0.004)
PMID 25620547 · one of two readings recorded this
lycopene AUC in TRL
n = 11
81.6 ± 32.1 nmol·hr/L TRL from red tomato juice, with significantly higher bioavailability from tangerine tomato juice (P<0.001)
PMID 25620547 · one of two readings recorded this
lycopene AUC in TRL
increases, n = 11
total lycopene of 690.9 ± 117.8 nmol·hr/L TRL from tangerine tomato juice
PMID 25620547 · one of two readings recorded this
lycopene bioavailability ratio, tangerine vs red tomato juice (AUC)
increases, p = 0.001, n = 11
lycopene from tangerine tomato juice was, on average, 8.5 times more bioavailable as compared lycopene from red tomato juice (P<0.001)
PMID 25620547 · one of two readings recorded this
lycopene fractional absorption
n = 11
The average (± SEM) fractional absorption of this 10 mg dose was 47.70 ± 8.81% from tangerine tomato and 4.98 ± 1.92% from red tomato
PMID 25620547 · one of two readings recorded this
lycopene fractional absorption
n = 11
The average (± SEM) fractional absorption of this 10 mg dose was 47.70 ± 8.81% from tangerine tomato and 4.98 ± 1.92% from red tomato
PMID 25620547 · one of two readings recorded this
plasma triglyceride-rich lipoprotein lycopene AUC over 12 h (HPLC-DAD-MS/MS) after 10 mg lycopene from tangerine (94% cis) versus red (10% cis) tomato juice, and fractional absorption
increases, lycopene approximately 8.5 times more bioavailable from tangerine than red tomato juice
Not recorded as a finding: the comparison was against another active treatment
Lycopene from tangerine tomato juice was, on average, approximately 8.5 times more bioavailable compared to red tomato juice.
PMID 25620547 · one of two readings recorded this
within-subject ratio of lycopene AUC, tangerine/red
increases, n = 11
The mean AUC tangerine/AUCred (± SEM) was 52.5 ± 22.0
PMID 25620547 · one of two readings recorded this
cis-lycopene isomer fraction, plasma
plasma and prostate isomers were 47 and 80 % cis
PMID 26202168 · one of two readings recorded this
cis-lycopene isomer fraction, prostate
plasma and prostate isomers were 47 and 80 % cis
PMID 26202168 · one of two readings recorded this
correlation of prostate lycopene with post-intervention plasma lycopene
increases, p = 0.001
Prostate lycopene concentration was moderately correlated with post-intervention plasma lycopene concentrations (r 0·60, P =0·001)
PMID 26202168 · one of two readings recorded this
end-of-study prostate lycopene concentration, fold vs control
increases, p = 0.001
The end-of-study prostate lycopene concentration was 0·16 (sem 0·02) nmol/g in the controls, but was 3·5-, 3·6- and 2·2-fold higher in tomato soup (P= 0·001), sauce (P= 0·001) and juice (P= 0·165) consumers, respectively
PMID 26202168 · one of two readings recorded this
end-of-study prostate lycopene concentration, fold vs control
increases, p = 0.001
The end-of-study prostate lycopene concentration was 0·16 (sem 0·02) nmol/g in the controls, but was 3·5-, 3·6- and 2·2-fold higher in tomato soup (P= 0·001), sauce (P= 0·001) and juice (P= 0·165) consumers, respectively
PMID 26202168 · one of two readings recorded this
end-of-study prostate lycopene concentration, fold vs control
no effect, p = 0.165
The end-of-study prostate lycopene concentration was 0·16 (sem 0·02) nmol/g in the controls, but was 3·5-, 3·6- and 2·2-fold higher in tomato soup (P= 0·001), sauce (P= 0·001) and juice (P= 0·165) consumers, respectively
PMID 26202168 · one of two readings recorded this
end-of-study prostate lycopene concentration
The end-of-study prostate lycopene concentration was 0·16 (sem 0·02) nmol/g in the controls, but was 3·5-, 3·6- and 2·2-fold higher in tomato soup (P= 0·001), sauce (P= 0·001) and juice (P= 0·165) consumers, respectively
PMID 26202168 · one of two readings recorded this
plasma lycopene concentration
decreases
the controls consuming the lycopene-restricted diet showed a decline in plasma lycopene concentration from 0·55 (sem 0·60) to 0·42 (sem 0·07) μmol/l ( - 24 %)
PMID 26202168 · one of two readings recorded this
plasma lycopene concentration
increases
0·48 (sem 0·09) to 0·82 (sem 0·12) μmol/l (71 %)
PMID 26202168 · one of two readings recorded this
plasma lycopene concentration
increases
from 0·68 (sem 0·1) to 1·13 (sem 0·09) μmol/l (66 %)
PMID 26202168 · one of two readings recorded this
plasma lycopene concentration
increases
0·49 (sem 0·12) to 0·78 (sem 0·1) μmol/l (59 %)
PMID 26202168 · one of two readings recorded this
Circulating lycopene dose-response, Begg's test for publication bias
no effect, p = 0.35
Begg's rank correlation test (P = 0.350) also indicated no publication bias
PMID 26287411 · one of two readings recorded this
Circulating lycopene dose-response, Egger's test for publication bias
p = 0.026
Egger's linear regression test (P = 0.026) indicated publication bias existed
PMID 26287411 · one of two readings recorded this
Dietary lycopene dose-response, Begg's test for publication bias
no effect, p = 0.2
Begg's rank correlation test (P = 0.200) and Egger's linear regression test (P = 0.220) indicated no publication bias
PMID 26287411 · one of two readings recorded this
Dietary lycopene dose-response, Egger's test for publication bias
no effect, p = 0.22
Begg's rank correlation test (P = 0.200) and Egger's linear regression test (P = 0.220) indicated no publication bias
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
decreases
0.95 96 (95% CI 0.93 to 0.99) for 10 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
no effect
0.88 (95% CI 0.75 to 1.05) for 100 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
no effect
0.89 (95% CI 0.74 to 1.08) for 110 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
decreases
0.92 (95% CI 0.86 to 0.97) for 20 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
decreases
0.88 (95% CI 0.80 to 0.96) for 30 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
decreases
0.86 (95% CI 0.77 to 0.95) for 40 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
decreases
0.85 (95% CI 0.76 to 0.94) for 60 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
decreases
0.86 (95% CI 0.77 to 0.94) for 70 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
decreases
0.87 (95% CI 0.76 to 0.99) for 80 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at circulating lycopene concentration vs 2.15 μg/dL reference
no effect
0.88 (95% CI 0.76 to 1.01) for 90 μg/dL
PMID 26287411 · one of two readings recorded this
Prostate cancer risk at dietary lycopene dose vs 0.1 mg reference
decreases
0.95 (95% CI 0.90 to 0.99) for 12 mg
PMID 26287411 · one of two readings recorded this